It’s melanoma, now what?

DecisionDx-Melanoma – helping physicians and patients

Melanoma is one of the most common cancers found among adults, aged 15-29, in the U.S. and the deadliest if not caught early. There are emerging technologies to help identify a patient’s risk for recurrence and metastasis such as gene expression profiling. Watch to learn more about how DecisionDx-Melanoma helps both physicians and patients

Dr. Farberg sits down with Teddi Mellencamp to discuss all things melanoma, the complexities that come along with a skin cancer diagnosis, and how DecisionDx-Melanoma provides personalized insights into each patient’s melanoma journey

  • How can someone access the test?

  • The ABCDEs of Melanoma

  • Early detection is key: The importance of skin checks with your dermatologist

  • Castle Biosciences and DecisionDx-Melanoma

  • What is DecisionDx-Melanoma?

  • Results and information provided by DecisionDx-Melanoma

  • Anxiety around a melanoma diagnosis

  • The cost of DecisionDx-Melanoma

  • How DecisionDx-Melanoma works and the data supporting it

  • Why self-advocacy matters in melanoma care: A dermatologist's insight